Literature DB >> 186612

Antibody-induced modulation and shedding of mammary tumor virus antigens on the surfaces of GR ascites leukemia cells as compared with normal antigens.

J Calafat, J Hilgers, W J Van Bitterswijk, M Verbeet, P C Hageman.   

Abstract

The distribution, antibody-induced redistribution, and shedding of murine mammary tumor virus (MuMTV) antigens and the surfaces of GR mouse ascites leukemia (GRSL) cells were studied by the immunoferritin technique and compared with the same activities of thy 1.2 and H-2.8 antigens. MuMTV antigens were redistributed easily and then largely shed from the cell surface; in contrast, H-2.8 antigen moved easily and probably was partially released from the plasms membrane and Thy 1.2 antigen moved slowly and was some what interiorized. The complement-dependent cytotoxicity test was used to study the possibility of antigenic modulation for these cell-surface antigens from the surface of the GRSL cells could be modulated by preincubation with anti-MuMTV serum, in contrast to H-2.8 and Thy 1.2 antigens. The results obtained with the immunoferritin technique and the cytotoxicity test correlated well and sug-ested that the shedding of MuMTV antigens from the cell surfaces may occur in vivo, providing the tumor a way to escape from the immune defense of the host. Thy 1.2 and H-2.8 antigens were present on the envolope of B and C particles, which suggested that these viruses do not select a Thy 1.2 or H-2.8-negative area of the GRSL cell surface as amaturation site.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 186612     DOI: 10.1093/jnci/56.5.1019

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  11 in total

1.  Antibody-induced modulation of Friend virus cell surface antigens decreases virus production by persistent erythroleukemia cells: influence of the Rfv-3 gene.

Authors:  B Chesebro; K Wehrly; D Doig; J Nishio
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

2.  Clearance of antibodies from rat sarcoma cell surfaces. Rate of clearance of alloantibodies depends on antibody isotype.

Authors:  S M Hobbs; J M Styles; C J Dean; P S Shepherd
Journal:  Immunology       Date:  1983-12       Impact factor: 7.397

3.  Immune complexes and circulating antibodies against autologous leukaemic cells in patients with acute leukaemias.

Authors:  M Bertini; G Galetto; P M Comoglio
Journal:  Immunology       Date:  1982-03       Impact factor: 7.397

4.  Tumour cell-antibody interactions. II. In vitro studies.

Authors:  G Froese; I Berczi; L G Israels
Journal:  Immunology       Date:  1982-02       Impact factor: 7.397

5.  Failure to detect soluble tumor associated antigen by radioimmunoassay in bovine lymphoma.

Authors:  R M Jacobs; V E Valli; B N Wilkie
Journal:  Can J Comp Med       Date:  1981-01

6.  In vitro modulation of viral cell surface glycoproteins by anti-viral antibody in the presence of complement.

Authors:  N T Gorman; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1982-12       Impact factor: 4.330

Review 7.  Fibrin as a component of the tumor stroma: origins and biological significance.

Authors:  H F Dvorak; D R Senger; A M Dvorak
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

8.  Antigenic modulation of Friend virus erythroleukemic cells in vitro by serum from mice with dormant erythroleukemia.

Authors:  E V Genovesi; P A Marx; E F Wheelock
Journal:  J Exp Med       Date:  1977-08-01       Impact factor: 14.307

9.  Antibody response of nude (RNU/RNU) and hairy (RNU/+) rats to circulating cell surface components from human pancreatic cancer xenografts.

Authors:  G Davies; A G Grant; D Duke; J Hermon-Taylor
Journal:  Br J Cancer       Date:  1983-08       Impact factor: 7.640

10.  Antigenic modulation of mammary tumour virus envelope antigen or GR thymic lymphoma cells in relation to expressions of H-2, TL cell-surface antigens and THY1.

Authors:  J Hilgers; A Sonnenberg; R Nusse
Journal:  Br J Cancer       Date:  1980-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.